Page last updated: 2024-09-04

moxifloxacin and Torsade de Pointes

moxifloxacin has been researched along with Torsade de Pointes in 29 studies

Research

Studies (29)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (48.28)	29.6817
2010's	13 (44.83)	24.3611
2020's	2 (6.90)	2.80

Authors

Authors	Studies
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B	1
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS	1
Bastogne, T; Champéroux, P; Fares, R; Le Guennec, JY; Richard, S; Thireau, J	1
Bian, S; Lei, W; Tang, X	1
Berg, A; Hanna, D; Hermann, D; Jamei, M; Patel, N; Polak, S; Romero, K	1
Berg, A; Hanna, D; Hatley, O; Hermann, D; Patel, N; Polak, S; Romero, K; Wisniowska, B	1
Ali, Z; Ismail, M; Khan, F; Khan, Q	1
Cheng, L; Fang, Y; Li, JQ	1
Barbey, JT; Beaty, B; Connolly, M; Krantz, MJ	1
Boussery, K; De Ridder, F; Gallacher, D; Marostica, E; Teisman, A; Van Ammel, K; Van Bocxlaer, J; Vermeulen, A	1
Vos, MA	1
Daubert, JP; DiSalle, M; Shah, AH; Sherazi, S	1
Badshah, A; Cotant, JF; Halabi, AR; Janjua, M; Younas, F	1
Andersen, MP; Graff, C; Kanters, JK; Matz, J; Nielsen, J; Struijk, JJ; Toft, E	1
Cristea, L; Farha, R; Jordan, P; Kolis, S; Lee, LS; Salgo, M; Zhang, X	1
Beekman, JD; de Boer, TP; Duker, G; Houtman, MJ; Jonsson, MK; Nalos, L; Peschar, M; Rook, MB; Sartipy, P; Thomsen, MB; van der Heyden, MA; van der Nagel, R; van Veen, TA; Varkevisser, R; Vos, MA	1
Aktürk, F; Kumbay, E; Mehmetoğlu, E; Tiryakioğlu, O; Tiryakioğlu, SK	1
Baas, T; Dössel, O; Gräfe, K; Khawaja, A	1
Chiba, K; Hagiwara, T; Hashimoto, K; Sugiyama, A; Takahashi, S; Takasuna, K	1
Cox, CD; Meyerrose, GE; Peeters, MJ; Seifert, CF; Tsikouris, JP	1
Crimin, K; Engtrakul, J; Fermini, B; Fossa, AA; O'Donnell, J; Wisialowski, T	1
Attevelt, NJ; Beekman, JD; Chiba, K; Sugiyama, A; Takahara, A; Thomsen, MB; Vos, MA	1
Falagas, ME; Rafailidis, PI; Rosmarakis, ES	1
Dale, KM; Kluger, J; Lertsburapa, K; White, CM	1
Breithardt, G; Cakir, Y; Eckardt, L; Engelen, MA; Haverkamp, W; Hilker, E; Milberg, P; Mönnig, G; Osada, N; Ramtin, S; Stypmann, J	1
Akyurek, O; Altin, T; Guldal, M; Karaoguz, R; Ongun Ozdemir, A; Ozcan, O; Turhan, S	1
Cox, BF; Gintant, GA; Limberis, JT; McDermott, JS; Wegner, CD	1
Grant, EM; Quintiliani, R; White, CM	1
Frothingham, R	1

Reviews

3 review(s) available for moxifloxacin and Torsade de Pointes

Article	Year
Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review. Expert opinion on drug safety, 2018, Volume: 17, Issue:10 Topics: Aged; Anti-Bacterial Agents; Electrocardiography; Fluoroquinolones; Humans; Long QT Syndrome; Moxifloxacin; Risk Assessment; Risk Factors; Torsades de Pointes	2018
Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability. British journal of pharmacology, 2008, Volume: 154, Issue:7 Topics: Animals; Aza Compounds; Cisapride; Dogs; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Fluoroquinolones; Humans; Models, Biological; Moxifloxacin; Quinolines; Rabbits; Risk Assessment; Terfenadine; Torsades de Pointes	2008
Arrhythmias associated with fluoroquinolone therapy. International journal of antimicrobial agents, 2007, Volume: 29, Issue:4 Topics: Anti-Bacterial Agents; Arrhythmias, Cardiac; Aza Compounds; Drug Interactions; Fluoroquinolones; Heart Rate; Humans; Long QT Syndrome; Moxifloxacin; Quinolines; Risk Factors; Torsades de Pointes	2007

Trials

4 trial(s) available for moxifloxacin and Torsade de Pointes

Article	Year
Man versus Machine: Comparison of Automated and Manual Methodologies for Measuring the QTc Interval: A Prospective Study. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2016, Volume: 21, Issue:1 Topics: Algorithms; Anti-Bacterial Agents; Cross-Over Studies; Diagnosis, Computer-Assisted; Dose-Response Relationship, Drug; Electrocardiography; Female; Fluoroquinolones; Heart Conduction System; Humans; Male; Moxifloxacin; Prospective Studies; Single-Blind Method; Torsades de Pointes	2016
Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization. Clinical pharmacology and therapeutics, 2010, Volume: 88, Issue:1 Topics: Adolescent; Adult; Algorithms; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Aza Compounds; Cardiovascular Agents; Data Interpretation, Statistical; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Female; Fluoroquinolones; Heart; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Risk Assessment; Sotalol; Torsades de Pointes; Young Adult	2010
Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. Journal of clinical pharmacology, 2012, Volume: 52, Issue:4 Topics: Adolescent; Adult; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Fluoroquinolones; HIV Protease Inhibitors; Humans; Least-Squares Analysis; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Ritonavir; Saquinavir; Torsades de Pointes; Young Adult	2012
Effects of three fluoroquinolones on QT analysis after standard treatment courses. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2006, Volume: 11, Issue:1 Topics: Analysis of Variance; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Levofloxacin; Long QT Syndrome; Male; Moxifloxacin; Ofloxacin; Quinolines; Statistics, Nonparametric; Torsades de Pointes	2006

Other Studies

22 other study(ies) available for moxifloxacin and Torsade de Pointes

Article	Year
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment. Journal of applied toxicology : JAT, 2012, Volume: 32, Issue:10 Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers	2012
MICE models: superior to the HERG model in predicting Torsade de Pointes. Scientific reports, 2013, Volume: 3 Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes	2013
Contribution of haemodynamic side effects and associated autonomic reflexes to ventricular arrhythmias triggering by torsadogenic hERG blocking drugs. British journal of pharmacology, 2022, Volume: 179, Issue:18 Topics: Animals; Arrhythmias, Cardiac; Dogs; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Ether-A-Go-Go Potassium Channels; Heart Rate; Long QT Syndrome; Moxifloxacin; Quinidine; Reflex; Torsades de Pointes	2022
A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin. BMC pulmonary medicine, 2020, Jun-24, Volume: 20, Issue:1 Topics: Acrylamides; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Male; Moxifloxacin; Mutation; Protein Kinase Inhibitors; Torsades de Pointes	2020
Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development. Journal of pharmacokinetics and pharmacodynamics, 2018, Volume: 45, Issue:3 Topics: Adult; Algorithms; Antitubercular Agents; Cardiotoxicity; Diarylquinolines; Drug Development; Electrocardiography; Female; Heart; Humans; Male; Moxifloxacin; Risk Assessment; Sensitivity and Specificity; Torsades de Pointes; Tuberculosis	2018
Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin. The AAPS journal, 2018, 03-14, Volume: 20, Issue:3 Topics: Algorithms; Anti-Bacterial Agents; ERG1 Potassium Channel; Heart; Humans; Long QT Syndrome; Models, Biological; Moxifloxacin; Risk Assessment; Torsades de Pointes; Translational Research, Biomedical	2018
[One case of torsades de pointes with Aase's syndrome induced by moxifloxacin]. Zhonghua xin xue guan bing za zhi, 2013, Volume: 41, Issue:1 Topics: Aged; Anemia, Diamond-Blackfan; Aza Compounds; Female; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Torsades de Pointes	2013
Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities. Journal of pharmacokinetics and pharmacodynamics, 2015, Volume: 42, Issue:6 Topics: Action Potentials; Animals; Anti-Bacterial Agents; Bayes Theorem; Dogs; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Fluoroquinolones; Heart Conduction System; Heart Rate; HEK293 Cells; Humans; Models, Animal; Models, Cardiovascular; Models, Statistical; Moxifloxacin; Patch-Clamp Techniques; Potassium Channel Blockers; Randomized Controlled Trials as Topic; Risk Assessment; Species Specificity; Torsades de Pointes; Toxicity Tests; Transfection; Translational Research, Biomedical	2015
Moxifloxacin-induced torsades de pointes. Cardiology journal, 2008, Volume: 15, Issue:1 Topics: Aged; Anti-Infective Agents; Aza Compounds; Electrocardiography; Fluoroquinolones; Humans; Male; Moxifloxacin; Quinolines; Torsades de Pointes	2008
Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug. The American journal of the medical sciences, 2009, Volume: 338, Issue:2 Topics: Anti-Infective Agents; Aza Compounds; Electrocardiography; Fluoroquinolones; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Torsades de Pointes	2009
Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes. British journal of pharmacology, 2012, Volume: 165, Issue:2 Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Aza Compounds; Cell Line; Disease Models, Animal; Dogs; Embryonic Stem Cells; Female; Fluoroquinolones; Heart; Heart Block; Humans; Methoxamine; Moxifloxacin; Myocytes, Cardiac; Phenethylamines; Piperidines; Potassium Channel Blockers; Pyridines; Quinolines; Rabbits; Sulfonamides; Torsades de Pointes; Ventricular Remodeling	2012
Moxifloxacin-dependent Torsades de Pointes. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2011, Volume: 11, Issue:6 Topics: Anti-Infective Agents; Aza Compounds; Diagnosis, Differential; Echocardiography; Electrocardiography; Female; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Quinolines; Torsades de Pointes	2011
Investigation of parameters highlighting drug induced small changes of the T-wave's morphology for drug safety studies. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2011, Volume: 2011 Topics: Anti-Infective Agents; Aza Compounds; Electrocardiography; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Quinolines; Tachycardia, Ventricular; Torsades de Pointes; United States; United States Food and Drug Administration	2011
In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. European journal of pharmacology, 2004, Feb-20, Volume: 486, Issue:2 Topics: Administration, Oral; Animals; Aza Compounds; Blood Pressure; Chloralose; Disease Models, Animal; Dogs; Electrocardiography; Female; Fluoroquinolones; Gatifloxacin; Halothane; Heart Block; Heart Rate; Infusions, Intravenous; Long QT Syndrome; Male; Moxifloxacin; Quinolines; Rabbits; Risk Assessment; Time Factors; Torsades de Pointes; Ventricular Function, Left	2004
Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. The Journal of pharmacology and experimental therapeutics, 2006, Volume: 318, Issue:1 Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Aza Compounds; Cell Line; Dose-Response Relationship, Drug; Erythromycin; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Guinea Pigs; Heart Rate; Humans; Ketolides; Moxifloxacin; Quinolines; Risk Factors; Torsades de Pointes	2006
No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block. British journal of pharmacology, 2006, Volume: 149, Issue:8 Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Arrhythmias, Cardiac; Aza Compounds; Azithromycin; Dogs; Dose-Response Relationship, Drug; Electric Stimulation; Electroencephalography; Electrophysiology; Fluoroquinolones; Heart Block; Heart Rate; Long QT Syndrome; Moxifloxacin; Phenethylamines; Quinolines; Sulfonamides; Torsades de Pointes	2006
Moxifloxacin and torsade de pointes. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:2 Topics: Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Electrocardiography; Female; Fluoroquinolones; Humans; Injections, Intravenous; Moxifloxacin; Quinolines; Torsades de Pointes; Treatment Outcome	2007
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. Journal of cardiovascular electrophysiology, 2007, Volume: 18, Issue:6 Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Electrophysiologic Techniques, Cardiac; Fluoroquinolones; Heart Conduction System; In Vitro Techniques; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Rabbits; Torsades de Pointes	2007
Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. The Canadian journal of cardiology, 2007, Volume: 23, Issue:11 Topics: Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bradycardia; Cardiac Pacing, Artificial; Female; Fluoroquinolones; Humans; Long QT Syndrome; Moxifloxacin; Pneumonia; Quinolines; Risk Factors; Syncope; Torsades de Pointes; Treatment Outcome	2007
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. Journal of cardiovascular pharmacology, 2001, Volume: 37, Issue:5 Topics: Action Potentials; Animals; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cisapride; Dogs; Erythromycin; Female; Fluoroquinolones; Imidazoles; In Vitro Techniques; Indoles; Long QT Syndrome; Male; Models, Biological; Moxifloxacin; Perfusion; Piperazines; Purkinje Fibers; Quinolines; Sotalol; Swine; Torsades de Pointes	2001
Moxifloxacin does increase the corrected QT interval. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Oct-15, Volume: 33, Issue:8 Topics: Anti-Infective Agents; Aza Compounds; Circadian Rhythm; Electrocardiography; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Quinolines; Torsades de Pointes	2001
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy, 2001, Volume: 21, Issue:12 Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Electrocardiography; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies; Torsades de Pointes	2001